Question 1
Regular
When monitoring a patient's response to interferon therapy, the nurse notes that the major dose-limiting factor for interferon therapy is which condition?
Correct!
Incorrect
The correct answer is: B
Rationale
Fatigue
Monitoring a patient's response to interferon therapy reveals that fatigue is the primary dose-limiting factor, as it significantly impacts the patient's quality of life and overall treatment adherence.
A: Diarrhea
While diarrhea can occur as a side effect, it does not usually limit the dosage of interferon therapy as significantly as fatigue does.
C: Anxiety
Anxiety can be a concern during treatment but does not typically serve as a major limiting factor for interferon dosage adjustments in patients.
D: Nausea and vomiting
Although nausea and vomiting may occur, they are generally manageable and do not represent the primary challenge in determining the maximum tolerated dose of interferon.
Correct Answer: B
Rationale: Fatigue
Monitoring a patient's response to interferon therapy reveals that fatigue is the primary dose-limiting factor, as it significantly impacts the patient's quality of life and overall treatment adherence.
A: Diarrhea
While diarrhea can occur as a side effect, it does not usually limit the dosage of interferon therapy as significantly as fatigue does.
C: Anxiety
Anxiety can be a concern during treatment but does not typically serve as a major limiting factor for interferon dosage adjustments in patients.
D: Nausea and vomiting
Although nausea and vomiting may occur, they are generally manageable and do not represent the primary challenge in determining the maximum tolerated dose of interferon.
Question 2
Regular
A patient asks about his cancer treatment with monoclonal antibodies. The nurse tells him that which is the major advantage of treating certain cancers with monoclonal antibodies?
Correct!
Incorrect
The correct answer is: C
Rationale
Monoclonal antibodies target certain tumor cells and yet bypass normal cells. This specificity allows for a more focused treatment, minimizing damage to healthy tissues while effectively attacking cancer cells, leading to improved patient outcomes.
A: They will help the patient improve more quickly than will other antineoplastic drugs. Speed of improvement varies among treatments and is not a guaranteed benefit of monoclonal antibodies.
B: They are more effective against metastatic tumors. Effectiveness can depend on various factors, including tumor type and individual patient response, not solely on the classification of the tumor.
D: There are fewer incidences of opportunistic infections with monoclonal antibodies. While they may have different side effects, opportunistic infections can still occur, as immune system impacts vary significantly among patients.
Correct Answer: C
Rationale: Monoclonal antibodies target certain tumor cells and yet bypass normal cells. This specificity allows for a more focused treatment, minimizing damage to healthy tissues while effectively attacking cancer cells, leading to improved patient outcomes.
A: They will help the patient improve more quickly than will other antineoplastic drugs. Speed of improvement varies among treatments and is not a guaranteed benefit of monoclonal antibodies.
B: They are more effective against metastatic tumors. Effectiveness can depend on various factors, including tumor type and individual patient response, not solely on the classification of the tumor.
D: There are fewer incidences of opportunistic infections with monoclonal antibodies. While they may have different side effects, opportunistic infections can still occur, as immune system impacts vary significantly among patients.
Question 3
Regular
During a patient's therapy with interleukins, the nurse monitors the patient for capillary leak syndrome. Which assessment finding, if present, would indicate this problem?
Correct!
Incorrect
The correct answer is: D
Rationale
A sudden, 15-pound weight gain would indicate capillary leak syndrome. This condition is characterized by significant fluid shift from vasculature to interstitial spaces, leading to sudden weight changes due to fluid retention.
A: Bradycardia indicates a slow heart rate, which may relate to various cardiac issues but does not specifically signal capillary leak syndrome and its associated fluid shifts.
B: A dry cough may suggest respiratory issues or side effects of medication but does not directly correlate with the fluid accumulation characteristic of capillary leak syndrome.
C: Bruising on the skin could indicate bleeding disorders or thrombocytopenia but is not a definitive sign of capillary leak syndrome, which primarily involves fluid retention and weight changes.
Correct Answer: D
Rationale: A sudden, 15-pound weight gain would indicate capillary leak syndrome. This condition is characterized by significant fluid shift from vasculature to interstitial spaces, leading to sudden weight changes due to fluid retention.
A: Bradycardia indicates a slow heart rate, which may relate to various cardiac issues but does not specifically signal capillary leak syndrome and its associated fluid shifts.
B: A dry cough may suggest respiratory issues or side effects of medication but does not directly correlate with the fluid accumulation characteristic of capillary leak syndrome.
C: Bruising on the skin could indicate bleeding disorders or thrombocytopenia but is not a definitive sign of capillary leak syndrome, which primarily involves fluid retention and weight changes.
Question 4
Regular
A patient who has received chemotherapy has a critically low platelet count. The nurse expects which drug or drug class to be used to stimulate platelet cell production?
Correct!
Incorrect
The correct answer is: C
Rationale
Oprelvekin is the drug expected to stimulate platelet cell production in a patient with a critically low platelet count following chemotherapy. This medication specifically enhances the production of platelets, addressing thrombocytopenia effectively.
A: Filgrastim primarily stimulates the production of neutrophils, not platelets, making it unsuitable for addressing low platelet counts in chemotherapy patients.
B: Interferons are used mainly for antiviral and antiproliferative effects but do not directly influence platelet production, rendering them ineffective for this specific scenario.
D: Epoetin alfa is designed to stimulate red blood cell production, not platelet generation, thus it does not address the issue of low platelet counts in this context.
Correct Answer: C
Rationale: Oprelvekin is the drug expected to stimulate platelet cell production in a patient with a critically low platelet count following chemotherapy. This medication specifically enhances the production of platelets, addressing thrombocytopenia effectively.
A: Filgrastim primarily stimulates the production of neutrophils, not platelets, making it unsuitable for addressing low platelet counts in chemotherapy patients.
B: Interferons are used mainly for antiviral and antiproliferative effects but do not directly influence platelet production, rendering them ineffective for this specific scenario.
D: Epoetin alfa is designed to stimulate red blood cell production, not platelet generation, thus it does not address the issue of low platelet counts in this context.
Question 5
Regular
A patient who has received chemotherapy has a steadily decreasing white blood cell count. The chemotherapy will end on Tuesday afternoon. The oncologist has mentioned that a colony-stimulating factor will be started soon. The nurse knows that the appropriate time to start this medication is when?
Correct!
Incorrect
The correct answer is: C
Rationale
The appropriate time to start the colony-stimulating factor is Wednesday afternoon, 24 hours after the chemotherapy ends. This timing allows for the chemotherapy's immediate effects to diminish, enabling the medication to effectively stimulate white blood cell recovery.
A: While the patient is still receiving chemotherapy. Starting the medication during chemotherapy may interfere with its effectiveness and not allow enough time for recovery stimulation.
B: Two hours after the chemotherapy ends. Initiating treatment too soon may not provide adequate time for the chemotherapy's impact to subside, limiting the medication's efficacy.
D: In 2 to 4 days, after the white blood cells have reached their nadir. Delaying treatment until after the nadir could prolong the patient's vulnerability to infection and delay recovery.
Correct Answer: C
Rationale: The appropriate time to start the colony-stimulating factor is Wednesday afternoon, 24 hours after the chemotherapy ends. This timing allows for the chemotherapy's immediate effects to diminish, enabling the medication to effectively stimulate white blood cell recovery.
A: While the patient is still receiving chemotherapy. Starting the medication during chemotherapy may interfere with its effectiveness and not allow enough time for recovery stimulation.
B: Two hours after the chemotherapy ends. Initiating treatment too soon may not provide adequate time for the chemotherapy's impact to subside, limiting the medication's efficacy.
D: In 2 to 4 days, after the white blood cells have reached their nadir. Delaying treatment until after the nadir could prolong the patient's vulnerability to infection and delay recovery.
Question 6
Regular
A patient has an order for the monoclonal antibody adalimumab. The nurse notes that the patient does not have a history of cancer. What is another possible reason for administering this drug?
Correct!
Incorrect
The correct answer is: B
Rationale
Adalimumab is commonly administered for rheumatoid arthritis, a chronic inflammatory condition affecting the joints. It helps reduce inflammation and pain, enhancing the patient's quality of life and functionality in daily activities.
A: Severe anemia This condition typically requires different treatment approaches, such as iron supplementation or erythropoiesis-stimulating agents, rather than a monoclonal antibody like adalimumab.
C: Thrombocytopenia While adalimumab may have some immunomodulatory effects, it is not specifically indicated for treating low platelet counts, which often require alternative therapies or careful monitoring.
D: Osteoporosis Adalimumab does not address osteoporosis, a condition characterized by reduced bone density, which is generally managed with bisphosphonates or other agents aimed at bone health.
Correct Answer: B
Rationale: Adalimumab is commonly administered for rheumatoid arthritis, a chronic inflammatory condition affecting the joints. It helps reduce inflammation and pain, enhancing the patient's quality of life and functionality in daily activities.
A: Severe anemia This condition typically requires different treatment approaches, such as iron supplementation or erythropoiesis-stimulating agents, rather than a monoclonal antibody like adalimumab.
C: Thrombocytopenia While adalimumab may have some immunomodulatory effects, it is not specifically indicated for treating low platelet counts, which often require alternative therapies or careful monitoring.
D: Osteoporosis Adalimumab does not address osteoporosis, a condition characterized by reduced bone density, which is generally managed with bisphosphonates or other agents aimed at bone health.
Question 7
Regular
During interleukin drug therapy, a patient is showing signs of severe fluid retention, with increasing dyspnea and severe peripheral edema. The next dose of the interleukin is due now. Which action will the nurse take next?
Correct!
Incorrect
The correct answer is: A
Rationale
Hold the drug, and notify the prescriber.
Given the patient's severe fluid retention, increasing dyspnea, and peripheral edema, administering the interleukin could exacerbate these complications. Prioritizing patient safety requires holding the dose and contacting the prescriber for further evaluation and guidance.
B: Give the drug, and notify the prescriber. Administering the drug in the face of such concerning symptoms risks further deterioration in the patient's condition, compromising their safety.
C: Give the drug along with acetaminophen and diphenhydramine. This option overlooks the critical need to assess and address the patient's severe symptoms before administering any medication, including the interleukin.
D: Monitor the patient for 2 hours, and then give the drug if the patient's condition improves. Delaying action while the patient shows severe symptoms could lead to worsened health outcomes and is not an appropriate response.
Correct Answer: A
Rationale: Hold the drug, and notify the prescriber.
Given the patient's severe fluid retention, increasing dyspnea, and peripheral edema, administering the interleukin could exacerbate these complications. Prioritizing patient safety requires holding the dose and contacting the prescriber for further evaluation and guidance.
B: Give the drug, and notify the prescriber. Administering the drug in the face of such concerning symptoms risks further deterioration in the patient's condition, compromising their safety.
C: Give the drug along with acetaminophen and diphenhydramine. This option overlooks the critical need to assess and address the patient's severe symptoms before administering any medication, including the interleukin.
D: Monitor the patient for 2 hours, and then give the drug if the patient's condition improves. Delaying action while the patient shows severe symptoms could lead to worsened health outcomes and is not an appropriate response.
Question 8
Regular
The nurse is administering an interferon and will implement which intervention?
Correct!
Incorrect
The correct answer is: D
Rationale
Rotating injection sites. This intervention is crucial when administering interferons, as it minimizes tissue irritation and potential adverse reactions, ensuring the medication remains effective and the patient's comfort is prioritized during treatment.
A: Giving the medication with meals. This option does not apply to interferons, as food intake does not impact their absorption or efficacy, thus not enhancing patient outcomes.
B: Monitoring daily weights. While important for overall health, this intervention specifically does not relate to the immediate administration of interferons or their direct side effects.
C: Limiting fluids while the patient is taking this medication. Fluid restriction is not necessary and could lead to dehydration, which may complicate the patient's condition rather than support treatment.
Correct Answer: D
Rationale: Rotating injection sites. This intervention is crucial when administering interferons, as it minimizes tissue irritation and potential adverse reactions, ensuring the medication remains effective and the patient's comfort is prioritized during treatment.
A: Giving the medication with meals. This option does not apply to interferons, as food intake does not impact their absorption or efficacy, thus not enhancing patient outcomes.
B: Monitoring daily weights. While important for overall health, this intervention specifically does not relate to the immediate administration of interferons or their direct side effects.
C: Limiting fluids while the patient is taking this medication. Fluid restriction is not necessary and could lead to dehydration, which may complicate the patient's condition rather than support treatment.
Question 9
Regular
Abatacept is prescribed for a patient with severe rheumatoid arthritis. The nurse checks the patient's medical history, knowing that this medication would need to be used cautiously if which condition is present?
Correct!
Incorrect
The correct answer is: B
Rationale
Abatacept should be used cautiously in patients with chronic obstructive pulmonary disease (COPD).
Chronic obstructive pulmonary disease (COPD) is a respiratory condition that can be exacerbated by immunosuppressive therapies like abatacept, potentially increasing the risk of respiratory infections and complications in patients with weakened immune responses.
A: Coronary artery disease may require careful management but does not have a direct contraindication with abatacept use, making it less of a concern.
C: Diabetes mellitus does not specifically necessitate caution with abatacept, although monitoring is essential for overall health management in these patients.
D: Hypertension does not pose a significant risk with the use of abatacept, as it primarily affects inflammatory pathways rather than blood pressure regulation.
Correct Answer: B
Rationale: Abatacept should be used cautiously in patients with chronic obstructive pulmonary disease (COPD).
Chronic obstructive pulmonary disease (COPD) is a respiratory condition that can be exacerbated by immunosuppressive therapies like abatacept, potentially increasing the risk of respiratory infections and complications in patients with weakened immune responses.
A: Coronary artery disease may require careful management but does not have a direct contraindication with abatacept use, making it less of a concern.
C: Diabetes mellitus does not specifically necessitate caution with abatacept, although monitoring is essential for overall health management in these patients.
D: Hypertension does not pose a significant risk with the use of abatacept, as it primarily affects inflammatory pathways rather than blood pressure regulation.
Question 10
Regular
Aldesleukin (IL-2) is prescribed for a patient. The nurse reviews the patient's medication list and would note a potential drug interaction if which drug class is also ordered?
Correct!
Incorrect
The correct answer is: D
Rationale
Aldesleukin (IL-2) has the potential to cause hypotension, which can be exacerbated by antihypertensive drugs. Therefore, if antihypertensives are also ordered, a significant drug interaction should be noted.
A: Anticoagulants Anticoagulants primarily affect blood clotting mechanisms rather than blood pressure regulation, making their interaction with aldesleukin less significant in terms of hypotensive effects.
B: Antiepileptic drugs Antiepileptic medications mainly focus on seizure control and do not influence blood pressure, resulting in minimal concern for interaction with aldesleukin's hypotensive properties.
C: Oral hypoglycemic drugs Oral hypoglycemics target blood sugar levels and have no direct impact on blood pressure, thus presenting no significant interaction with aldesleukin in the context of hypotension.
Correct Answer: D
Rationale: Aldesleukin (IL-2) has the potential to cause hypotension, which can be exacerbated by antihypertensive drugs. Therefore, if antihypertensives are also ordered, a significant drug interaction should be noted.
A: Anticoagulants Anticoagulants primarily affect blood clotting mechanisms rather than blood pressure regulation, making their interaction with aldesleukin less significant in terms of hypotensive effects.
B: Antiepileptic drugs Antiepileptic medications mainly focus on seizure control and do not influence blood pressure, resulting in minimal concern for interaction with aldesleukin's hypotensive properties.
C: Oral hypoglycemic drugs Oral hypoglycemics target blood sugar levels and have no direct impact on blood pressure, thus presenting no significant interaction with aldesleukin in the context of hypotension.
Question 11
Multiple Choice
During therapy with hematopoietic drugs, the nurse will monitor the patient for which adverse effects? (Select all that apply.)
Correct!
Incorrect
The correct answer is: B,C,E,F
Rationale
During therapy with hematopoietic drugs, the nurse will monitor the patient for edema, diarrhea, nausea and vomiting, and headache.
Monitoring for these adverse effects is essential as hematopoietic drugs can lead to fluid retention, gastrointestinal disturbances, and central nervous system impacts, making it crucial for nurses to observe any emerging symptoms to ensure patient safety and therapeutic effectiveness.
A: Hypotension. This option does not align with the primary side effects associated with hematopoietic drugs, which are more related to gastrointestinal and fluid balance issues.
D: Black, tarry stools. While gastrointestinal effects may occur, black, tarry stools typically indicate more serious conditions like gastrointestinal bleeding rather than a common adverse effect of hematopoietic therapy.
F: Headache. Although headaches can occur, they are less frequently highlighted as significant adverse effects compared to edema, diarrhea, nausea, and vomiting linked to hematopoietic drug administration.
Correct Answer: B,C,E,F
Rationale: During therapy with hematopoietic drugs, the nurse will monitor the patient for edema, diarrhea, nausea and vomiting, and headache.
Monitoring for these adverse effects is essential as hematopoietic drugs can lead to fluid retention, gastrointestinal disturbances, and central nervous system impacts, making it crucial for nurses to observe any emerging symptoms to ensure patient safety and therapeutic effectiveness.
A: Hypotension. This option does not align with the primary side effects associated with hematopoietic drugs, which are more related to gastrointestinal and fluid balance issues.
D: Black, tarry stools. While gastrointestinal effects may occur, black, tarry stools typically indicate more serious conditions like gastrointestinal bleeding rather than a common adverse effect of hematopoietic therapy.
F: Headache. Although headaches can occur, they are less frequently highlighted as significant adverse effects compared to edema, diarrhea, nausea, and vomiting linked to hematopoietic drug administration.
Question 12
Calculation(ans only)
A patient is to receive filgrastim 5 mcg/kg/day. The patient weighs 176 pounds. Identify how many micrograms of medication this patient will receive each day.
Correct!
Incorrect
The correct answer is: 400 MCG
Rationale
400 mcg.
To determine the dosage, first convert the patient's weight from pounds to kilograms: 176 lbs is approximately 80 kg. Multiplying 80 kg by 5 mcg/kg/day yields a total of 400 mcg daily, confirming the calculated dosage aligns with the prescribed treatment plan.
A: 200 mcg This dose results from miscalculating the weight conversion or dosage multiplier, leading to an underestimation of the required medication for effective treatment.
B: 800 mcg This figure arises from an incorrect interpretation of the dosage instructions, mistakenly doubling the calculated amount rather than adhering to the established guidelines of 5 mcg/kg/day.
C: 600 mcg This number suggests a misunderstanding of the weight-to-dosage relationship, inaccurately applying the weight conversion without proper multiplication, thus inflating the required medication amount.
Correct Answer: 400 MCG
Rationale: 400 mcg.
To determine the dosage, first convert the patient's weight from pounds to kilograms: 176 lbs is approximately 80 kg. Multiplying 80 kg by 5 mcg/kg/day yields a total of 400 mcg daily, confirming the calculated dosage aligns with the prescribed treatment plan.
A: 200 mcg This dose results from miscalculating the weight conversion or dosage multiplier, leading to an underestimation of the required medication for effective treatment.
B: 800 mcg This figure arises from an incorrect interpretation of the dosage instructions, mistakenly doubling the calculated amount rather than adhering to the established guidelines of 5 mcg/kg/day.
C: 600 mcg This number suggests a misunderstanding of the weight-to-dosage relationship, inaccurately applying the weight conversion without proper multiplication, thus inflating the required medication amount.
Question 13
Calculation(ans only)
A patient will be receiving aldesleukin (IL-2) (Proleukin), 600,000 IU/kg every 8 hours for 14 doses. The patient weighs 220 pounds. Identify how many IU of medication this patient will receive per dose.
Correct!
Incorrect
The correct answer is: 60 MILLION (60,000,000)
Rationale
60 million (60,000,000)
The patient weighs 220 pounds, which converts to approximately 100 kg. At a dosage of 600,000 IU/kg, the total per dose is calculated as 600,000 IU/kg multiplied by 100 kg, resulting in 60 million IU per dose.
A: 6 million (6,000,000) This calculation represents only 10% of the actual dosage and does not align with the weight of the patient or prescribed dose.
B: 600,000 (600,000) This figure reflects the IU per kg but fails to account for the patient's total weight, significantly underestimating the required dosage.
C: 600 million (600,000,000) This amount grossly exaggerates the dosage, miscalculating the weight-based administration and resulting in an unrealistic total for the patient's treatment.
Correct Answer: 60 MILLION (60,000,000)
Rationale: 60 million (60,000,000)
The patient weighs 220 pounds, which converts to approximately 100 kg. At a dosage of 600,000 IU/kg, the total per dose is calculated as 600,000 IU/kg multiplied by 100 kg, resulting in 60 million IU per dose.
A: 6 million (6,000,000) This calculation represents only 10% of the actual dosage and does not align with the weight of the patient or prescribed dose.
B: 600,000 (600,000) This figure reflects the IU per kg but fails to account for the patient's total weight, significantly underestimating the required dosage.
C: 600 million (600,000,000) This amount grossly exaggerates the dosage, miscalculating the weight-based administration and resulting in an unrealistic total for the patient's treatment.
Quiz Complete!
Biologic Response?Modifying and Antirheumatic Drugs
0%
0
out of
13
questions correct